Atlas Trials

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

Clinical trial NCT00645307 · COMPLETED

Trial details

NCT number
NCT00645307
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2004-05-01
Enrollment
235

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.